Article
Medicine, Research & Experimental
Jaekwon Seok, Hee Jeong Kwak, Yeonjoo Kwak, Moonjung Lee, Kyoung Sik Park, Aram Kim, Ssang-Goo Cho
Summary: This study investigates the effects of androgen suppression therapy on bladder cancer progression and identifies potential therapeutic targets. It is found that dutasteride, a 5 alpha-reductase inhibitor, can inhibit cell proliferation and migration of bladder cancer cells by regulating the expression of cancer progression proteins. Additionally, the study reveals the role of the target gene SRD5A1 in bladder cancer and its correlation with patient survival.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Urology & Nephrology
Jordan J. Kramer, Lin Gu, Daniel Moreira, Gerald Andriole, Ilona Csizmadi, Stephen J. Freedland
Summary: This study analyzed the association between statin use and the incidence of LUTS in asymptomatic men, as well as the progression of LUTS in symptomatic men. The results showed no significant relationship between statin use and either LUTS incidence or progression. Therefore, statins do not appear to play a role in the prevention or management of LUTS.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Molly E. DeWitt-Foy, Kristina Gam, Charles Modlin, Simon P. Kim, Robert Abouassaly
Summary: The study aimed to examine racial disparities in decisional regret among African American men with prostate cancer. Findings revealed that African American men experienced higher levels of decisional regret, partially explained by medical mistrust and concerns about masculinity.
JOURNAL OF UROLOGY
(2021)
Article
Medicine, General & Internal
Daisuke Obinata, Ken Nakahara, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi, Satoru Takahashi
Summary: In this retrospective study, the characteristics of prostate biopsies in patients treated with dutasteride were investigated. The results suggest that dutasteride may have a role in screening for prostate cancer, especially in older patients with abnormal MRI findings.
Article
Endocrinology & Metabolism
Jordan J. Kramer, Lin Gu, Daniel Moreira, Gerald Andriole, Stephen J. Freedland, Ilona Csizmadi
Summary: In older men, smoking does not increase the risk of developing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in asymptomatic men, nor does it affect the progression of LUTS in symptomatic men.
Article
Biochemistry & Molecular Biology
Aleksandar Kuzmanov, Souzan Salemi, Florian A. A. Schmid, Irene A. A. Burger, Daniel Eberli, Benedikt Kranzbuhler
Summary: PSMA-based imaging is a promising diagnostic tool for detecting prostate cancer, but low PSMA expression can limit its effectiveness. Inducing PSMA expression pharmacologically may improve the detection rate. In this study, we found that treatment with low concentrations of dutasteride (Duta) and lovastatin (Lova) significantly upregulated PSMA expression in prostate cancer cells. Combination treatment with lower concentrations of Duta and Lova further enhanced PSMA expression compared to single compound treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Urology & Nephrology
Yao Zhu, Miao Mo, Yu Wei, Junlong Wu, Jian Pan, Stephen J. Freedland, Ying Zheng, Dingwei Ye
Summary: Asia is traditionally considered to have a low incidence of prostate cancer, but the incidence and mortality of prostate cancer have rapidly increased across the continent in recent years. Significant differences in epidemiological features of prostate cancer have been observed among different Asian regions.
NATURE REVIEWS UROLOGY
(2021)
Article
Oncology
Jasmine Lim, Rohan Malek, J. R. Sathiyananthan, Charng C. Toh, Murali Sundram, Susan Y. Y. Woo, Noor A. M. Yusoff, Guan C. Teh, Benjamin J. T. Chui, Ing S. Ngu, S. Thevarajah, Wei J. Koh, Say B. Lee, Say C. Khoo, Boon W. Teoh, Rohana Zainal, Teck M. Tham, Shamsuddin Omar, Noor A. Nasuha, Hideyuki Akaza, Teng A. Ong
Summary: Prostate cancer is the third most common cancer in Malaysia, with a lifetime risk of 1 in 117 men. The longitudinal M-CaP Study investigated the clinical characteristics, treatment patterns, and outcomes of multi-ethnic Asian men with prostate cancer. Late-stage cancer diagnosis remains a challenge, with curative radiotherapy and androgen deprivation therapy being common treatments for advanced disease. Early detection is crucial for improving treatment outcomes and survival in prostate cancer patients.
Article
Oncology
Jane B. Vaselkiv, Carl Ceraolo, Kathryn M. Wilson, Claire H. Pernar, Emily M. Rencsok, Konrad H. Stopsack, Sydney T. Grob, Anna Plym, Edward L. Giovannucci, Aria F. Olumi, Adam S. Kibel, Mark A. Preston, Lorelei A. Mucci
Summary: The use of 5-alpha reductase inhibitor (5-ARI) is not associated with an increased risk of lethal prostate cancer or cancer-specific death, but is instead linked to a reduced risk of overall and localized disease. These findings suggest that 5-ARI use is safe in terms of prostate cancer mortality.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Biochemistry & Molecular Biology
Tianhong Pan, Song-Chang Lin, Yu-Chen Lee, Guoyu Yu, Jian H. Song, Jing Pan, Mark Titus, Robert L. Satcher, Theocharis Panaretakis, Christopher Logothetis, Li-Yuan Yu-Lee, Sue-Hwa Lin
Summary: The study demonstrates that statins can reduce bone marrow adiposity and slow down the progression of prostate cancer in bones. By affecting the transition of BMSC to adipocytes, the progression of PCa may be delayed.
Article
Radiology, Nuclear Medicine & Medical Imaging
Rossano Girometti, Gianluca Giannarini, Valeria Panebianco, Silvio Maresca, Lorenzo Cereser, Maria De Martino, Stefano Pizzolitto, Martina Pecoraro, Vincenzo Ficarra, Chiara Zuiani, Claudio Valotto
Summary: This study compared the impact of different PSA density (PSAD) thresholds on the accuracy of the Prostate Imaging Reporting And Data System v.2.1 (PI-RADSv2.1) in diagnosing clinically significant prostate cancer (csPCa). The results showed that PI-RADSv2.1 category four with PSAD >= 0.10 ng/mL ml(-1) was the biopsy-triggering cut-off with the highest net benefit within the expected prevalence range for csPCa.
BRITISH JOURNAL OF RADIOLOGY
(2022)
Article
Multidisciplinary Sciences
Hiromichi Ishiyama, Hideyasu Tsumura, Hisato Nagano, Motoi Watanabe, Eiichi Mizuno, Masashi Taka, Hiroaki Kobayashi, Takahisa Eriguchi, Hajime Imada, Koji Inaba, Katsumasa Nakamura
Summary: This study reported outcomes and risk factors of ultrahypofractionated radiotherapy for Japanese prostate cancer patients. The results showed that initial prostate-specific antigen levels and neoadjuvant androgen deprivation therapy were risk factors for biochemical recurrence, while biologically effective dose was associated with late genitourinary and gastrointestinal toxicities. The study concluded that ultrahypofractionated radiotherapy provided effective and safe treatment for Japanese prostate cancer patients, but higher prescribed doses might lead to higher toxicity rates.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Darren M. C. Poon, Kuen Chan, Tim Chan, Foo-Yiu Cheung, Daisy Lam, Martin Lam, Ka-Suet Law, Conrad Lee, Eric K. C. Lee, Angus Leung, Henry Sze, Chi-Chung Tong, Kenneth C. W. Wong, Philip Kwong
Summary: This review discusses the impacts of Asian ethnicity on metastatic prostate cancer treatment, including environmental, sociocultural, and genetic factors. The clear inter-ethnic differences in drug tolerability, serious adverse events, and genetic heterogeneity must be considered when treating patients and designing future precision studies.
Article
Cell Biology
Haleema Azam, Shane Maher, Shane Clarke, William M. Gallagher, Maria Prencipe
Summary: Inhibition of androgen receptor (AR) co-factor SRF provides a promising approach for overcoming resistance to current AR inhibitors in prostate cancer. Three small molecules (CCG-1423, CCG-257081, and lestaurtinib) can effectively reduce cell viability and induce cell cycle arrest and decreased proliferation, either singly or in combination with enzalutamide.
Article
Urology & Nephrology
Paige K. Kuhlmann, Sean C. Fischer, Lauren E. Howard, Daniel M. Moreira, Gerald L. Andriole, Martin L. Hopp, Claus G. Roehrborn, Donald L. Bliwise, Stephen J. Freedland
Summary: In men with poor sleep who complain of nocturia, treatment of lower urinary tract symptoms with dutasteride modestly improves nocturia but has no effect on sleep.
JOURNAL OF UROLOGY
(2021)